2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Clinical results from Enterin trial
Biotech company Enterin has announced the results of their phase 2 clinical trial of ENT-01 indicating that it had a positive benefit on the gut symptoms associated with Parkinson’s.
The mannitol pilot study results
The findings of a randomised, blinded clinical trial of the sweetener mannitol have been published. The results indicate that the molecule is safe and tolerable, but the study has not replicated the benefits that had previously been reported.
Exercise and Parkinson’s
It is a well-known fact that exercise is important for our general wellbeing. Recently, there has been a lot of new research published indicating that exercise could also potentially improve the lives of people with Parkinson’s. In late 2019, the results of a clinical trial…
A year in review: our 2021 research funding update
Despite a challenging year caused by COVID-19, Cure Parkinson’s has not been deterred in its efforts to identify and progress novel therapies to slow, stop and reverse Parkinson’s in 2021.
Tackling toxic alpha-synuclein
Three major lines of clinical investigation are currently underway to determine if stopping the clustering of alpha-synuclein in Parkinson’s can help to slow down the progression of the disease.